Effect of Linagliptin on the Ratio of Apoptosis Regulators in the Model of Non-Alcoholic Fatty Liver Disease in db/db Mice

We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin on the expression of apoptosis regulator proteins Bcl-2 and Bad in the liver of db / db mice with genetically determined obesity and type 2 diabetes mellitus. The mice received daily linagliptin or saline (placebo) by gava...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2019-06, Vol.167 (2), p.210-214
Main Authors: Michurina, S. V., Cherepanova, M. A., Ishchenko, I. Yu, Arkhipov, S. A., Klimontov, V. V., Zav’yalov, E. L.
Format: Article
Language:English
Subjects:
Animals
Apoptosis
Apoptosis - drug effects
Bcl-2 protein
bcl-Associated Death Protein - metabolism
Biomedical and Life Sciences
Biomedicine
Cell Biology
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Dipeptidyl-peptidase IV
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Fatty liver
Hepatocytes
Internal Medicine
Laboratory Medicine
Linagliptin
Linagliptin - therapeutic use
Liver
Liver diseases
Male
Mice
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - metabolism
Obesity
Obesity - drug therapy
Obesity - metabolism
Pathology
Peptidase
Proteins
Proto-Oncogene Proteins c-bcl-2 - metabolism
Rodents
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We studied the effects of dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin on the expression of apoptosis regulator proteins Bcl-2 and Bad in the liver of db / db mice with genetically determined obesity and type 2 diabetes mellitus. The mice received daily linagliptin or saline (placebo) by gavage from week 10 to week 18 of life. In the liver of non-treated mice, the area positively stained for Bad was greater than the area of Bcl-2 expression, which created the conditions for apoptosis activation in liver at this age. Administration of linagliptin decreased Bad stained area and increased Bcl-2 stained area in the liver cells. At the same time, Bad stained area remained larger in treated mice than the area of Bcl-2 expression area, which attested to partial normalization of pro- and antiapoptotic protein balance.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-019-04493-1